The multiple sclerosis study published in the journal The Lancet found that alemtuzumab significantly reduced the number of attacks or relapses by people with MS.
This result was seen both in patients who had not previously received any treatment and those who have continued to show disease activity while taking an existing treatment for MS.
In one trial with patients who had recently relapsed, new episodes were reduced by 49% more than that achieved by the current standard treatment.
Over a two-year period, 65% of patients on alemtuzumab compared with 47% of patients on interferon did not relapse.
More top news
David Cameron is expected to announce a new plan that will see Britain take in thousands more Syrian refugees.
Reports Ed Miliband is to rule out a return to frontline politics have been described as "speculation" by sources close to the politician.
Designer brand Hugo Boss faces a hefty fine for health and safety breaches after a boy was crushed to death by an 18-stone mirror